By Scientia Professor Vlado Perkovic

Journal articles

Zhang H; Rizk DV; Perkovic V; Maes B; Kashihara N; Rovin B; Trimarchi H; Sprangers B; Meier M; Kollins D; Papachristofi O; Milojevic J; Junge G; Nidamarthy PK; Charney A; Barratt J, 2024, 'Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy', Kidney International, 105, pp. 189 - 199, http://dx.doi.org/10.1016/j.kint.2023.09.027

Heerspink HJL; Perkovic V; Tuttle KR; Pergola PE; Mahaffey KW; Patel UD; Ishida JH; Kuo A; Chen F; Kustra R; Petrovic V; Rossing P; Kashihara N; Chertow GM, 2024, 'Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial', Journal of the American Society of Nephrology, http://dx.doi.org/10.1681/ASN.0000000000000444

Talbot B; Davies S; Burman J; Ritchie A; Snelling P; Lynch S; Park Y; Jones B; Garvey V; Jaure A; Jardine M; Perkovic V; Gallagher M; Brandwood A; Kaur N; Knight J, 2024, 'The Point-of-Care Peritoneal Dialysis System Early Evaluation Study (POC-PDEE): A pilot proof-of-principal study of the Ellen Medical Devices Point-of-Care affordable peritoneal dialysis system', Peritoneal Dialysis International, http://dx.doi.org/10.1177/08968608231209850

Ketema DB; Wallace H; Neuen BL; Kotwal SS; Ronksley PE; Badve S; Perkovic V; Gallagher MP; Joshi R; Jun M, 2024, 'Assessing the Quality of Care for People with CKD: A Systematic Review and Meta-Analysis', Journal of the American Society of Nephrology, 35, http://dx.doi.org/10.1681/asn.2024bzcfkb63

Siriwardana A; Jardine M; Perkovic V; Jun M; Kotwal SS; Arnott CG; Neuen BL, 2024, 'Cardiovascular, Kidney, and Safety Outcomes with Canagliflozin in Older Adults: A Pooled Secondary Analysis of the CANVAS Program and CREDENCE Trial', Journal of the American Society of Nephrology, 35, http://dx.doi.org/10.1681/asn.2024e59ygyz9

Rizk DV; Kollins D; Papachristofi O; Hach T; Valentin M-A; Merkel T; Renfurm RW; Perkovic V, 2024, 'Effect of Iptacopan on Proteinuria and Complement Biomarkers in IgAN: Interim Analysis of the Phase 3 APPLAUSE-IgAN Study', Journal of the American Society of Nephrology, 35, http://dx.doi.org/10.1681/asn.2024atyr04b6

Pratley RE; Mahaffey KW; Mann JF; Tuttle KR; Rossing P; Idorn T; David J-P; Bosch-Traberg H; Jeppesen OK; Bax WA; Gillard P; Arici M; Shamkhalova M; Perkovic V, 2024, 'Effect of Semaglutide on Mortality Outcomes in the FLOW Trial', Journal of the American Society of Nephrology, 35, http://dx.doi.org/10.1681/asn.20249xpc35vs

Ha JT; Hiremath S; Jun M; Green SC; Wheeler DC; Coyne DW; Perkovic V; Badve SV, 2024, 'Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease.', NEJM Evid, 3, pp. EVIDoa2300189, http://dx.doi.org/10.1056/EVIDoa2300189

Neuen BL; Ferguson TW; Jardine M; Neal B; Perkovic V; Bakris GL; Agarwal R; Schloemer P; Farjat AE; Jongs N; Heerspink HJL; Wheeler DC; Chertow GM; Tangri N, 2024, 'Prognostic Enrichment Using the Klinrisk Model: Insights from Landmark Kidney Disease Clinical Trials', Journal of the American Society of Nephrology, 35, http://dx.doi.org/10.1681/asn.2024c0crz6n5

Yeung EK; Ferguson TW; Tangri N; Vaduganathan M; Arnott CG; Jun M; Kotwal SS; Jardine M; Perkovic V; Heerspink HJL; Neuen BL, 2024, 'Risk-Based Implementation of SGLT2 Inhibitors: Insights from the CANVAS Program and CREDENCE Trial', Journal of the American Society of Nephrology, 35, http://dx.doi.org/10.1681/asn.2024k6fn2ax5

Rizk DV; Kollins D; Papachristofi O; Hach T; Jacinto-Sanders S; Merkel T; Schmouder RL; Kulmatycki KM; Renfurm RW; Perkovic V, 2024, 'Safety and Efficacy of Iptacopan in Patients with IgA Nephropathy with Baseline eGFR 20 to <30 mL/min: Phase 3 APPLAUSE-IgAN Subcohort Results', Journal of the American Society of Nephrology, 35, http://dx.doi.org/10.1681/asn.20241h4rz9f5

Tuttle KR; Mann JF; Sokareva E; Rayner B; Pugliese G; Pratley RE; Perkovic V; Mahaffey KW; Kashihara N; Jeppesen OK; Gumprecht J; Correa-Rotter R; Cherney D; Bosch-Traberg H; Arici M; Rossing P, 2024, 'Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of CKD Severity in the FLOW Trial', Journal of the American Society of Nephrology, 35, http://dx.doi.org/10.1681/asn.2024bjyvcgfe

Perkovic A; Webster E; Ridker P; Tuttle K; Perkovic V; Neuen B, 2024, 'The Effects of Anti-Inflammatory Agents on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomised Controlled Clinical Trials', Heart, Lung and Circulation, 33, pp. S539 - S539, http://dx.doi.org/10.1016/j.hlc.2024.06.904

Wong MG; Lv J; Neuen B; Monaghan H; Billot L; Perkovic V; Zhang H; Kim D, 2024, 'WCN24-1001 EFFECT OF CORTICOSTEROIDS ON KIDNEY AND SAFETY OUTCOMES IN IGA NEPHROPATHY ACROSS DIFFERENT LEVELS OF PROTEINURIA AND EGFR: A POST HOC ANALYSIS OF THE TESTING STUDY', Kidney International Reports, 9, pp. S151 - S151, http://dx.doi.org/10.1016/j.ekir.2024.02.310

Perkovic V; Kollins D; Renfurm R; Papachristofi O; Jacinto-Sanders S; Merkel T; Hach T; Rizk DV, 2024, 'WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY', Kidney International Reports, 9, pp. S506 - S506, http://dx.doi.org/10.1016/j.ekir.2024.02.1414

Trimarchi H; Barratt J; Radhakrishnan J; Rizk DV; Sorensen B; Leiske J; Khawaja Z; Campbell K; Perkovic V, 2024, 'WCN24-1837 BEYOND: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF ZIGAKIBART IN ADULTS WITH IGA NEPHROPATHY', Kidney International Reports, 9, pp. S177 - S177, http://dx.doi.org/10.1016/j.ekir.2024.02.362

Barratt J; Rovin B; Murphy E; Komers R; Trimarchi H; Perkovic V, 2024, 'WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL', Kidney International Reports, 9, pp. S505 - S506, http://dx.doi.org/10.1016/j.ekir.2024.02.1413

Heerspink HJL; Jongs N; Schloemer P; Little DJ; Brinker M; Tasto C; Karpefors M; Wheeler DC; Bakris G; Perkovic V; Nkulikiyinka R; Rossert J; Gasparyan SB, 2023, 'Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression', Journal of the American Society of Nephrology, 34, pp. 2025 - 2038, http://dx.doi.org/10.1681/ASN.0000000000000243

Fletcher RA; Jongs N; Chertow GM; McMurray JJV; Arnott C; Jardine MJ; Mahaffey KW; Perkovic V; Rockenschaub P; Rossing P; Correa-Rotter R; Toto RD; Vaduganathan M; Wheeler DC; Heerspink HJL; Neuen BL, 2023, 'Effect of SGLT2 Inhibitors on Discontinuation of Renin–angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials', Journal of the American Society of Nephrology, 34, pp. 1965 - 1975, http://dx.doi.org/10.1681/ASN.0000000000000248

Yu J; Sweeting AN; Gianacas C; Houston L; Lee V; Fletcher RA; Perkovic V; Li Q; Neuen BL; Berwanger O; Heerspink HJL; de Zeeuw D; Arnott C, 2023, 'The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial', Diabetes, Obesity and Metabolism, 25, pp. 3724 - 3735, http://dx.doi.org/10.1111/dom.15267

Marx N; Deanfield JE; Gerward S; Hovingh GK; Plunde O; Pratley RE; Staerk-Ostergaard J; Perkovic V, 2023, 'Prevalence of systemic inflammation in individuals with atherosclerotic cardiovascular disease: baseline characteristics from the SELECT, SOUL and FLOW phase 3 trials of semaglutide', European Heart Journal, 44, http://dx.doi.org/10.1093/eurheartj/ehad655.2751

Neuen BL; Perkovic V; Bakris GL; Lambers Heerspink H; Vaduganathan M, 2023, 'Abstract 17437: Estimated Lifetime Benefits of Combination Therapy With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-Steroidal MRAs in Patients With Type 2 Diabetes and Albuminuria', Circulation, 148, http://dx.doi.org/10.1161/circ.148.suppl_1.17437

Heerspink HJL; Vart P; Jongs N; Neuen BL; Bakris G; Claggett B; Vaduganathan M; McCausland F; Docherty KF; Jhund PS; Solomon SD; Perkovic V; McMurray JJV, 2023, 'Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials', Diabetes, Obesity and Metabolism, 25, pp. 3327 - 3336, http://dx.doi.org/10.1111/dom.15232

Rossing P; Baeres FMM; Bakris G; Bosch-Traberg H; Gislum M; Gough SCL; Idorn T; Lawson J; Mahaffey KW; Mann JFE; Mersebach H; Perkovic V; Tuttle K; Pratley R, 2023, 'The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease', Nephrology Dialysis Transplantation, 38, pp. 2041 - 2051, http://dx.doi.org/10.1093/ndt/gfad009

Januzzi JL; Mohebi R; Liu Y; Sattar N; Heerspink HJL; Tefera E; Vaduganathan M; Butler J; Yavin Y; Li J; Pollock CA; Perkovic V; Neal B; Hansen MK, 2023, 'Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial', Circulation, 148, pp. 651 - 660, http://dx.doi.org/10.1161/CIRCULATIONAHA.123.065251

Singh AK; Mccausland FR; Claggett BL; Wanner C; Wiecek A; Atkins MB; Carroll K; Perkovic V; Mcmurray JJV; Wittes J; Snapinn S; Blackorby A; Meadowcroft A; Barker T; Dimino T; Mallett S; Cobitz AR; Solomon SD, 2023, 'Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents - post hoc analyses of the ASCEND-ND and ASCEND-D trials', Nephrology Dialysis Transplantation, 38, pp. 1890 - 1897, http://dx.doi.org/10.1093/ndt/gfac342

Sridhar VS; Neuen BL; Fletcher RA; Slee A; Ang FG; Rapattoni W; Arnott C; Cherney DZ; Perkovic V; Wheeler DC; Levin A, 2023, 'Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials', Diabetes, Obesity and Metabolism, 25, pp. 2331 - 2339, http://dx.doi.org/10.1111/dom.15112

Kang A; Smyth B; Neuen BL; Heerspink HJL; Di Tanna GL; Zhang H; Arnott C; Hockham C; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Mahaffey KW; Perkovic V; Jardine MJ, 2023, 'The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials', Diabetes, Obesity and Metabolism, 25, pp. 2151 - 2162, http://dx.doi.org/10.1111/dom.15091

Fletcher RA; Arnott C; Rockenschaub P; Schutte AE; Carpenter L; Vaduganathan M; Agarwal R; Bakris G; Chang TI; Heerspink HJL; Jardine MJ; Mahaffey KW; Neal B; Pollock C; Jun M; Rodgers A; Perkovic V; Neuen BL, 2023, 'Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials', Journal of the American Heart Association, 12, pp. e028516, http://dx.doi.org/10.1161/JAHA.122.028516

Inker LA; Collier W; Greene T; Miao S; Chaudhari J; Appel GB; Badve SV; Caravaca-Fontán F; Del Vecchio L; Floege J; Goicoechea M; Haaland B; Herrington WG; Imai E; Jafar TH; Lewis JB; Li PKT; Maes BD; Neuen BL; Perrone RD; Remuzzi G; Schena FP; Wanner C; Wetzels JFM; Woodward M; Heerspink HJL; Estacio RO; Hanratty R; Chalmers J; Canetta P; Barrett B; Neal B; Perkovic V; Mahaffey KW; Johnson D; Jardine M; von Eynatten M; Verde E; Verdalles U; Arroyo D; Chapman A; Torres V; Yu A; Brosnahan G; Hannedouche T; Chow KM; Szeto CC; Leung CB; Xie D; Hou FF; Dwyer J; Pohl MA; Raz I; Hunsicker LG; Vanacker A; Malfait T; Maschio G; Locatelli F; Blankestijn PJ; van Zuilen A; Kobayashi F; Makino H; Chan JCN; Andrulli S; Pozzi C; Casartelli D; Praga M; Trujillo H; Cavero T; Sevillano A; Ruggenenti P; Perna A; Carrara F; Keane WF; Manno C; Haynes R; Baigent C; Landray M; Rauen T; Seikrit C; Wied S; Toto RD; de Jong PE; Saddelli M, 2023, 'A meta-analysis of GFR slope as a surrogate endpoint for kidney failure', Nature Medicine, 29, pp. 1867 - 1876, http://dx.doi.org/10.1038/s41591-023-02418-0

Yi TW; Wong MMY; Neuen BL; Arnott C; Poirier P; Seufert J; Slee A; Rapattoni W; Ang FG; Wheeler DC; Mahaffey KW; Perkovic V; Levin A, 2023, 'Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial', Diabetes, Obesity and Metabolism, 25, pp. 2043 - 2047, http://dx.doi.org/10.1111/dom.15065

Heerspink HJL; Jongs N; Neuen BL; Schloemer P; Vaduganathan M; Inker LA; Fletcher RA; Wheeler DC; Bakris G; Greene T; Chertow GM; Perkovic V, 2023, 'Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials', Kidney International, 104, pp. 181 - 188, http://dx.doi.org/10.1016/j.kint.2023.03.037

Yi TW; Smyth B; Di Tanna GL; Arnott C; Cardoza K; Kang A; Pollock C; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Heerspink HJL; Neal B; Wheeler DC; Cannon CP; Zhang H; Zinman B; Perkovic V; Levin A; Mahaffey KW; Jardine M; Brenner BM; Greene T; Jardine MJ; Meininger G; Li N; Kolesnyk I; Aizenberg D; Pecoits-Filho R; Cherney D; Obrador G; Chertow G; Chang T; Hawley C; Ji L; Wada T; Jha V; Lim SK; Lim-Abrahan MA; Santos F; Chae DW; Hwang SJ; Vazelov E; Rychlík I; Hadjadj S; Krane V; Rosivall L; De Nicola L; Dreval A; Nowicki M; Schiller A; Distiller L; Górriz JL; Kolesnyk M; David ; Wheeler C; Guerrero RAA; Albisu JP; Alvarisqueta A; Bartolacci I; Berli MA; Bordonava A; Calella P; Cantero MC; Cartasegna LR; Cercos E; Coloma GC; Colombo H; Commendatore V; Cuadrado J; Cuneo CA; Cusumano AM; Douthat WG; Dran RD; Farias E; Fernandez MF; Finkelstein H; Fragale G; Fretes JO; Garcia NH; Gastaldi A; Gelersztein E; Glenny JA; Gonzalez JP; Colaso PDCG; Goycoa C; Greloni GC; Guinsburg A; Hermida S; Juncos LI; Klyver MI; Kraft F; Krynski F; Lanchiotti PV; Leon de la Fuente RA; Marchetta N; Mele P; Nicolai S; Novoa PA; Orio SI, 2023, 'Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial', American Journal of Kidney Diseases, 82, pp. 84 - 96.e1, http://dx.doi.org/10.1053/j.ajkd.2022.12.015

Singh AK; Claggett BL; Perkovic V; Hiemstra T; Khavandi K; Lukas MA; Ranganathan P; Shannon JB; van Adelsberg J; Solomon S, 2023, '#3807 HEART FAILURE IN ASCEND-ND AND ASCEND-D', Nephrology Dialysis Transplantation, 38, http://dx.doi.org/10.1093/ndt/gfad063c_3807

Perkovic V; Barratt J; Radhakrishnan J; Rizk D; Trimarchi H; Khawaja Z; Leiske J; Sorensen B; King A; Jones-Burton C; Campbell K, 2023, '#4333 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BION-1301 IN ADULTS WITH IGA NEPHROPATHY', Nephrology Dialysis Transplantation, 38, http://dx.doi.org/10.1093/ndt/gfad063c_4333

Charytan DM; Mahaffey KW; Jardine MJ; Cannon CP; Neal B; Lambers Heerspink HJ; Agarwal R; Bakris GL; De Zeeuw D; Levin A; Pollock C; Zhang H; Zinman B; Rosenthal N; Perkovic V; Di Tanna GL; Yu J; Rogers K; Arnott C; Wheeler DC, 2023, 'Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering', BMJ Open Diabetes Research and Care, 11, pp. e003270, http://dx.doi.org/10.1136/bmjdrc-2022-003270

Mathur VS; Bushinsky DA; Inker L; Klaerner G; Li E; Parsell D; Perkovic V; Stasiv Y; Walker M; Wesson DE; Wheeler DC; Tangri N, 2023, 'Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis', Nephrology Dialysis Transplantation, 38, pp. 1448 - 1458, http://dx.doi.org/10.1093/ndt/gfac289

van der Hoek S; Jongs N; Oshima M; Neuen BL; Stevens J; Perkovic V; Levin A; Mahaffey KW; Pollock C; Greene T; Wheeler DC; Jardine MJ; Heerspink HJL, 2023, 'Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial', Clinical journal of the American Society of Nephrology : CJASN, 18, pp. 748 - 758, http://dx.doi.org/10.2215/CJN.0000000000000161

Heerspink HJL; Radhakrishnan J; Alpers CE; Barratt J; Bieler S; Diva U; Inrig J; Komers R; Mercer A; Noronha IL; Rheault MN; Rote W; Rovin B; Trachtman H; Trimarchi H; Wong MG; Perkovic V; Alarmartine E; Chae DW; Del Vecchio L; Floege J; Hwang SJ; Jelakovic B; Maes B; Malecki R; Miglinas M; Nolasco FEB; Praga M; Rabindranath K; Rosenberg M; Tang SCW; Tesar V; Bose B; Gangadharan M; McDonald S; Peh C; Jahan S; Yeap C; Clayton P; Irish G; Thyagarajan N; Hollett P; Krishnasamy R; Carroll R; Jesudason S; Crail S; Coates T; Waugh J; Noble E; Mahadevan K; Campbell V; Salehi T; Lim W; Boudville N; Chakera A; Chan D; Krishnan A; Eqbal Y; Gillies A; Vilayur E; Maung Myint TM; Gray N; Cheetham M; Pollock C; Cooper B; Mather A; Roxburgh S; Shen Y; Stangenberg S; Siriwardana A; O'Lone E; Wan S; Neuen B; Tsun Kit Ha J; Kim D; Heath L; Jain A; Phua E; Li Y; Gallagher M; Jardine M; Ritchie A; Razavian M; Foote C; Wyndham R; Sen S; Endre Z; Erlich J; Fernando M; Yong K; Luxton G; Kotwal S; Roger S; Wijeratne V; Packham D; Fraser I; Vandewiele B; Laute M; Lemahieu W; Jamar S, 2023, 'Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial', The Lancet, 401, pp. 1584 - 1594, http://dx.doi.org/10.1016/S0140-6736(23)00569-X

Koshino A; Oshima M; Arnott C; Fletcher RA; Bakris GL; Jardine M; Mahaffey KW; Perkovic V; Pollock C; Heerspink HJL; Neuen BL, 2023, 'Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial', Diabetes, Obesity and Metabolism, 25, pp. 1413 - 1418, http://dx.doi.org/10.1111/dom.14978

Barratt J; Rovin B; Wong MG; Alpers CE; Bieler S; He P; Inrig J; Komers R; Heerspink HJL; Mercer A; Noronha IL; Radhakrishnan J; Rheault MN; Rote W; Trachtman H; Trimarchi H; Perkovic V, 2023, 'IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study', Kidney International Reports, 8, pp. 1043 - 1056, http://dx.doi.org/10.1016/j.ekir.2023.02.1086

Rizk DV; Rovin BH; Zhang H; Kashihara N; Maes B; Trimarchi H; Perkovic V; Meier M; Kollins D; Papachristofi O; Charney A; Barratt J, 2023, 'Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study', Kidney International Reports, 8, pp. 968 - 979, http://dx.doi.org/10.1016/j.ekir.2023.01.041

Zhang YM; Lv JC; Wong MG; Zhang H; Perkovic V, 2023, 'Glucocorticoids for IgA nephropathy—pro', Kidney International, 103, pp. 666 - 669, http://dx.doi.org/10.1016/j.kint.2023.01.018

Neuen BL; Bello AK; Levin A; Lunney M; Osman MA; Ye F; Ashuntantang GE; Bellorin-Font E; Gharbi MB; Davison S; Ghnaimat M; Harden P; Jha V; Kalantar-Zadeh K; Kerr PG; Klarenbach S; Kovesdy CP; Luyckx V; Ossareh S; Perl J; Rashid HU; Rondeau E; See EJ; Saad S; Sola L; Tchokhonelidze I; Tesar V; Tungsanga K; Kazancioglu RT; Wang AYM; Yang CW; Zemchenkov A; Zhao MH; Jager KJ; Caskey FJ; Perkovic V; Jindal KK; Okpechi IG; Tonelli M; Feehally J; Harris DC; Johnson DW, 2023, 'National health policies and strategies for addressing chronic kidney disease: Data from the International Society of Nephrology Global Kidney Health Atlas', PLOS Global Public Health, 3, http://dx.doi.org/10.1371/journal.pgph.0001467

Jain SS; Yu J; Arnott C; Neal B; Perkovic V; Neuen BL; Jardine M; Mahaffey KW, 2023, 'Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial', International Journal of Cardiology, 395, http://dx.doi.org/10.1016/j.ijcard.2023.131444

Heerspink HJ; Agarwal R; Bakris GL; Cherney D; Lam CSP; Neuen BL; Tuttle KR; Wanner C; Brinker MD; Dizayee S; Kolkhof P; Schloemer P; Vesterinen PH; Perkovic V, 2023, 'Design and Baseline Characteristics of the FIND-CKD Trial: Efficacy of Finerenone on Kidney Disease Progression in People with Non-Diabetic CKD', Journal of the American Society of Nephrology, 34, pp. 678 - 678, http://dx.doi.org/10.1681/asn.20233411s1678a

Tangri N; Ferguson TW; Bamforth RJ; Arnott CG; Mahaffey KW; Heerspink HJ; Perkovic V; Neuen BL, 2023, 'External Validation of a Machine Learning Model for Progression of CKD in the CREDENCE and CANVAS Trials', Journal of the American Society of Nephrology, 34, pp. 418 - 419, http://dx.doi.org/10.1681/asn.20233411s1418c

Ha J; Hiremath S; Jun M; Palmer S; Wheeler DC; Coyne DW; Perkovic V; Badve S, 2023, 'Long-Term Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in CKD: A Systematic Review and Meta-Analysis of Randomized Trials', Journal of the American Society of Nephrology, 34, pp. 367 - 367, http://dx.doi.org/10.1681/asn.20233411s1367a

Jun M; Wick J; Neuen BL; Kotwal SS; Badve S; Chalmers JP; Jardine M; Perkovic V; Gallagher MP; Ronksley PE, 2023, 'The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset', Journal of the American Society of Nephrology, 34, pp. 373 - 373, http://dx.doi.org/10.1681/asn.20233411s1373a

Jain SS; Yu J; Arnott C; Neal BC; Perkovic V; Neuen B; Jardine M; Mahaffey KW, 2023, 'TREATMENT EFFECT OF CANAGLIFLOZIN FOR PATIENTS ON THERAPY FOR HEART FAILURE: POOLED ANALYSIS OF THE CANVAS PROGRAM AND CREDENCE TRIAL', Journal of the American College of Cardiology, 81, pp. 283, http://dx.doi.org/10.1016/s0735-1097(23)00727-1

Back to profile page